Isadora Sousa de Oliveira

Prof. Isadora Sousa de Oliveira

School of Pharmaceutical Sciences of Ribeirão Preto - University of São Paulo
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
Karla De Castro Figueiredo BordonKarla De Castro Figueiredo Bordon
Karla De Castro Figueiredo Bordon
CCCamila Takeno Cologna
Camila Takeno Cologna
EFElisa Corrêa Fornari-Baldo
Elisa Corrêa Fornari-Baldo
EPErnesto Lopes Pinheiro-Júnior
Ernesto Lopes Pinheiro-Júnior
FCFelipe Augusto Cerni
Felipe Augusto Cerni
Eliane Candiani ArantesEliane Candiani Arantes
Eliane Candiani Arantes
Animal poisons and venoms are comprised of different classes of molecules displaying wide-ranging pharmacological activities. This review aims to provide an in-depth view of toxin-based compounds from terrestrial and marine organisms used as diagnostic tools, experimental molecules to validate postulated therapeutic targets, drug libraries, prototypes for the design of drugs, cosmeceuticals, and therapeutic agents. However, making these molecules applicable requires extensive preclinical trials, with some applications also demanding clinical trials, in order to validate their molecular target, mechanism of action, effective dose, potential adverse effects, as well as other fundamental parameters. Here we go through the pitfalls for a toxin-based potential therapeutic drug to become eligible for clinical trials and marketing. The manuscript also presents an overview of the current picture for several molecules from different animal venoms and poisons (such as those from amphibians, cone snails, hymenopterans, scorpions, sea anemones, snakes, spiders, tetraodontiformes, bats, and shrews) that have been used in clinical trials. Advances and perspectives on the therapeutic potential of molecules from other underexploited animals, such as caterpillars and ticks, are also reported. The challenges faced during the lengthy and costly preclinical and clinical studies and how to overcome these hindrances are also discussed for that drug candidates going to the bedside. It covers most of the drugs developed using toxins, the molecules that have failed and those that are currently in clinical trials. The article presents a detailed overview of toxins that have been used as therapeutic agents, including their discovery, formulation, dosage, indications, main adverse effects, and pregnancy and breastfeeding prescription warnings. Toxins in diagnosis, as well as cosmeceuticals and atypical therapies (bee venom and leech therapies) are also reported. The level of cumulative and detailed information provided in this review may help pharmacists, physicians, biotechnologists, pharmacologists, and scientists interested in toxinology, drug discovery, and development of toxin-based products.

6 September 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
Manuela Berto PuccaManuela Berto Pucca
Manuela Berto Pucca
FCFelipe A. Cerni
Felipe A. Cerni
Isadora Sousa de OliveiraIsadora Sousa de Oliveira
Isadora Sousa de Oliveira
Timothy P. JenkinsTimothy P. Jenkins
Timothy P. Jenkins
LALídia Argemí
Lídia Argemí
Andreas LaustsenAndreas Laustsen
Andreas Laustsen
Honey bees can be found all around the world and fulfill key pollination roles within their natural ecosystems, as well as in agriculture. Most species are typically docile, and most interactions between humans and bees are unproblematic, despite their ability to inject a complex venom into their victims as a defensive mechanism. Nevertheless, incidences of bee stings have been on the rise since the accidental release of Africanized bees to Brazil in 1956 and their subsequent spread across the Americas. These bee hybrids are more aggressive and are prone to attack, presenting a significant healthcare burden to the countries they have colonized. To date, treatment of such stings typically focuses on controlling potential allergic reactions, as no specific antivenoms against bee venom currently exist. Researchers have investigated the possibility of developing bee antivenoms, but this has been complicated by the very low immunogenicity of the key bee toxins, which fail to induce a strong antibody response in the immunized animals. However, with current cutting-edge technologies, such as phage display, alongside the rise of monoclonal antibody therapeutics, the development of a recombinant bee antivenom is achievable, and promising results towards this goal have been reported in recent years. Here, current knowledge on the venom biology of Africanized bees and current treatment options against bee envenoming are reviewed. Additionally, recent developments within next-generation bee antivenoms are presented and discussed.

22 October 2020 in Toxins
Verified
Journal Article
Open access
PDF file
Manuela Berto PuccaManuela Berto Pucca
Manuela Berto Pucca
CKCecilie Knudsen
Cecilie Knudsen
Isadora Sousa de OliveiraIsadora Sousa de Oliveira
Isadora Sousa de Oliveira
CRCharlotte Rimbault
Charlotte Rimbault
Felipe CerniFelipe Cerni
Felipe Cerni
Wuelton MonteiroWuelton Monteiro
Wuelton Monteiro
Snake ‘dry bites’ are characterized by the absence of venom being injected into the victim during a snakebite incident. The dry bite mechanism and diagnosis are quite complex, and the lack of envenoming symptoms in these cases may be misinterpreted as a miraculous treatment or as proof that the bite from the perpetrating snake species is rather harmless. The circumstances of dry bites and their clinical diagnosis are not well-explored in the literature, which may lead to ambiguity amongst treating personnel about whether antivenom is indicated or not. Here, the epidemiology and recorded history of dry bites are reviewed, and the clinical knowledge on the dry bite phenomenon is presented and discussed. Finally, this review proposes a diagnostic and therapeutic protocol to assist medical care after snake dry bites, aiming to improve patient outcomes.

1 April 2017 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
JBJohara Boldrini-França
Johara Boldrini-França
CCCamila Takeno Cologna
Camila Takeno Cologna
Manuela Berto PuccaManuela Berto Pucca
Manuela Berto Pucca
Karla De Castro Figueiredo BordonKarla De Castro Figueiredo Bordon
Karla De Castro Figueiredo Bordon
FAFernanda Gobbi Amorim
Fernanda Gobbi Amorim
Eliane Candiani ArantesEliane Candiani Arantes
Eliane Candiani Arantes

1 January 2022 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
Isadora Sousa de OliveiraIsadora Sousa de Oliveira
Isadora Sousa de Oliveira
LCLarissa Soares Cardoso
Larissa Soares Cardoso
IFIsabela Ferreira
Isabela Ferreira
GAGabriel Melo Alexandre-Silva
Gabriel Melo Alexandre-Silva
BJBeatriz de Cássia da Silva Jacob
Beatriz de Cássia da Silva Jacob
Manuela Berto PuccaManuela Berto Pucca
Manuela Berto Pucca
Over the years, vaccinations have provided significant advances in public health, because they substantially reduce the morbimortality of vaccine-preventable diseases. Nevertheless, many people are still hesitant to be vaccinated. Brazil is a region of many anti-vaccine movements, and several outbreaks of vaccine-preventable diseases, such as yellow fever and measles, have occurred in the country during the last few years. To avoid new outbreaks, immunization coverage must be high; however, this is a great challenge to achieve due to the countless anti-vaccine movements. The World Health Organization has suggested new actions for the next decade via the Immunization Agenda 2030 to control, reduce, or eradicate vaccine-preventable diseases. Nonetheless, the vaccination coverage has decreased recently. To resolve the anti-vaccine issue, it is necessary to propose a long-term approach that involves innovative education programs on immunization and critical thinking, using different communication channels, including social media. Cooperation among biology and health scientists, ethicists, human scientists, policymakers, journalists, and civil society is essential for an in-depth understanding of the social action of vaccine refusal and planning effective education measures to increase the vaccine coverage.

1 January 2023 in Journal of Venomous Animals and Toxins including Tropical Diseases
Verified
Journal Article
Open access
PDF file
GAGabriela de Oliveira Almeida
Gabriela de Oliveira Almeida
Isadora Sousa de OliveiraIsadora Sousa de Oliveira
Isadora Sousa de Oliveira
Eliane Candiani ArantesEliane Candiani Arantes
Eliane Candiani Arantes
Suely Vilela SampaioSuely Vilela Sampaio
Suely Vilela Sampaio
Snake venom disintegrins are low molecular weight, non-enzymatic proteins rich in cysteine, present in the venom of snakes from the families Viperidae, Crotalidae, Atractaspididae, Elapidae, and Colubridae. This family of proteins originated in venom through the proteolytic processing of metalloproteinases (SVMPs), which, in turn, evolved from a gene encoding an A Disintegrin And Metalloprotease (ADAM) molecule. Disintegrins have a recognition motif for integrins in their structure, allowing interaction with these transmembrane adhesion receptors and preventing their binding to proteins in the extracellular matrix and other cells. This interaction gives disintegrins their wide range of biological functions, including inhibition of platelet aggregation and antitumor activity. As a result, many studies have been conducted in an attempt to use these natural compounds as a basis for developing therapies for the treatment of various diseases. Furthermore, the FDA has approved Tirofiban and Eptifibatide as antiplatelet compounds, and they are synthesized from the structure of echistatin and barbourin, respectively. In this review, we discuss some of the main functional and structural characteristics of this class of proteins and their potential for therapeutic use.